tradingkey.logo

BUZZ-NeoGenomics rises on better-than-expected 2025 revenue forecast

ReutersJan 15, 2025 1:32 PM

Shares of cancer testing services co NeoGenomics NEO.O rise ~5% to $14.47 premarket

NEO forecast FY 2025 revenue in the range of $735 mln to $745 mln vs analysts' average estimate of $727.70 mln - data compiled by LSEG

10 of 15 brokerages rate stock "buy" or higher and 5 "hold"; their median PT is $19.50 - data compiled by LSEG

NEO gained 3.3% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI